Internationally renowned diabetes expert proposed to join Diamyd Medical’s Board of Directors

One of the world’s most prominent diabetes experts, Professor Mark Atkinson, American Diabetes Association Eminent Scholar for Diabetes Research; Director, UF Diabetes Institute; University of Florida, Gainesville, FL, USA, is proposed to join Diamyd Medical’s Board of Director’s at the upcoming Annual General Meeting of Shareholders on November 15, 2018.  Re-election is proposed - for Chairman: Erik Nerpin, LL.M in International Banking and Attorney at Law, Stockholm; and for Directors: Anders Essen-Möller, M. Sc. and Founder of the Company, Chairman of NextCell Pharma AB, Stockholm; Torbjörn Bäckström, Professor and Head of Neurosteroid Research at Umeå Research Centre, CEO of Umecrine AB, Umeå;  and Maria-Teresa Essen-Möller, M.Sc. and CEO of Health Solutions AB, Stockholm.

“Having followed Diamyd Medical as a scientific advisor over many years, it is with great enthusiasm I will join the Company’s Board of Directors,” says Professor Mark Atkinson. “I will do my best to continue to make a difference for those with type 1 diabetes”.

“Mark Atkinson is bringing invaluable expertise and experience to our Board,“ says Anders Essen-Möller, founder and Board member of Diamyd Medical. “As our therapeutic diabetes vaccine is entering into late stage development it is imperative we are the top of mind choice regarding future international strategic developments for finding a cure for the disease.”

Dr Atkinson's research extends to understanding the immunological mechanisms underlying the formation of type 1 diabetes, with a primary goal to develop an effective method for preventing and reversing the disease.

“We are extremely proud and honored to welcome this world-leading expert in diabetes to take active part in Diamyd Medical,” says Ulf Hannelius, President and CEO of Diamyd Medical.

The Annual General Meeting of Diamyd Medical for the fiscal year 2017/2018 will be held on November 15, 2018, at 5 pm. at hotel Kung Carl, Birger Jarlsgatan 21 in Stockholm. Presentations are planned for by Professor Per-Ola Carlsson, Uppsala University Hospital and University of Uppsala, and Professor Johnny Ludvigsson, Linköping University. Professor Atkinson may participate for part of the meeting by video-call.

About Diamyd Medical 
Diamyd Medical is dedicated to finding a cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, for antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. Diamyd® has demonstrated good safety in trials with more than 1,000 patients as well as effect in some pre-specified subgroups. Besides the Company’s own European Phase-II trial DIAGNODE-2, where the diabetes vaccine is administered directly into the lymph node, there are four investigator initiated clinical trials ongoing with Diamyd®. Diamyd Medical also develops Remygen®, an oral GABA-based investigational drug. An investigator-initiated trial in patients with type 1 diabetes since at least five years has started at Uppsala University Hospital. An investigator-initiated placebo-controlled trial with GABA and Diamyd® in patients recently diagnosed with type 1 diabetes is ongoing at the University of Alabama at Birmingham. Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd® and Remygen® key assets. Diamyd Medical is also one of the major shareholders in the stem cell company NextCell Pharma AB and has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq First North under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser.

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

This information is information that Diamyd Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, 10.15 CET on November 1, 2018


Attachments:

  PDF version